Theratechnologies Inc. (NASDAQ: THTX) had its "buy" rating re-affirmed by analysts at Canaccord Genuity. They now have a $8.00 price target on the stock.
Theratechnologies Inc. - Common Shares (THTX)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
THTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THTX alerts
High impacting Theratechnologies Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
THTX
News
- Theratechnologies Announces Update on its Preclinical Oncology Research Program [Yahoo! Finance]Yahoo! Finance
- Theratechnologies Announces Update on its Preclinical Oncology Research Program [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Theratechnologies Announces Update on its Preclinical Oncology Research ProgramGlobeNewswire
- Theratechnologies Appoints Jordan Zwick to its Board of DirectorsGlobeNewswire
- Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
THTX
Sec Filings
- 3/22/24 - Form 6-K
- 3/22/24 - Form 6-K
- 3/21/24 - Form 6-K
- THTX's page on the SEC website